Summary. The 
Introduction
Previous studies (Kendle, 1975) have shown RMI 12,936 to be of interest due to its high antifertility activity in the pregnant rat coupled with its negligible oestrogenic activity. Termination of pregnancy by administration of RMI 12,936 was associated with significant ovarian hypertrophy but conclu¬ sions on the mechanism of action of the compound were tentative. It was believed that the com¬ pound could not simply inhibit progesterone synthesis as the antifertility effect could not be reversed by progesterone implants. Failure to displace progesterone from uterine cytosol binding protein made it unlikely, however, that RMI 12,936 was a competitive antagonist of progesterone. Further investigations were therefore undertaken to elucidate the mechanisms involved.
These investigations indicated that RMI 12,936 interrupted ovarian progesterone production. Consideration of the molecular structure of RMI 12,936 and of the process of progesterone bio¬ synthesis led to the possibility that RMI 12,936 was most likely to inhibit progesterone biosynthesis by acting as an alternative substrate for the A53-ketosteroid isomerase enzyme which normally controls 5 to 4 isomerization following 3ß-dehydrogenation of pregnenolone (Cheatum & Warren, to the Porton strain used before in their response to RMI 12,936 in antifertility and vaginal cornification assays. Steroids were suspended in an aqueous vehicle containing 0-25% sodium carboxymethylcellulose (w/v) and 1 % Tween 80 (w/v 110-4,147-4, 82-5 and 95T mg/pair in Groups 1-4 respectively. Analysis of these results showed that, compared with the control Group 1, the Group 2 mean was significantly increased (P < 0-01) while the means of Groups 3 and 4 were significantly reduced (P < 0-01 and < 0-05). The means of Groups 3 and 4, however, were not significantly different from each other (P > 0-05).
These results confirm the previous indication (Kendle, 1975) (Fieser, 1953 The results given in Table 3 show that Isomer 201 and RMI 12,936 were approximately equal in uterotrophic activity. Cross-reactions of RMI 12,936 and Isomer 201 were studied using the method described by Johansson (1969) . Graded amounts of each steroid were added to assay tubes and the amount producing 50% depression of activity determined. This value was related to the amount of pro¬ gesterone producing 50 % depression and the percentage cross-reaction determined.
The results showed that the cross-reactions of RMI 12,936 and Isomer 201 were 0-51 and 7-8 % of the activity of progesterone respectively. The extraction from plasma by petroleum ether of RMI 12,936 was 100% so its effective cross-reaction in the assay was also 0-51 %. The The results showed that the mean systemic progesterone level in pregnant rats was 10-3 ng/ml 24 hr after ovariectomy compared to 65-0 ng/ml in intact controls. Administration of 2 mg Isomer 201/rat increased the apparent progesterone concentration in pregnant ovariectomized rats to 23-1 ng/ml due to its effective cross-reaction in the assay. In intact pregnant rats treated with Isomer 201 the assayed level of progesterone was 67-3 ng/ml. After making allowance for the cross-reaction of Isomer 201 in the assay there was no evidence of a significant reduction in progesterone production in pregnant rats given Isomer 201 compared with that in pregnant controls.
Discussion
Previous studies (Kendle, 1975) have shown that administration of RMI 12,936 terminated preg¬ nancy following administration on Day 1 in the rat by causing acceleration of tubai transport followed by expulsion of fertilized eggs via the vagina. The results of the present study indicate that fertility is regained at the end of a period equivalent to the duration of normal pregnancy in animals given this treatment. This indicates that the effects of RMI 12,936 are readily reversible but further indicates that the drug has no effect on the lifespan of the corpora lutea of pregnancy as the treated animals returned to oestrus at approximately the same time as the pregnant controls produced their litters. This finding is of particular interest as it may reasonably have been expected that following termina¬ tion of pregnancy before implantation the lifespan of corpora lutea would have been confined to the 10-14 days characteristic of pseudopregnancy, as is the case following treatment with oestrogens (K. E. Kendle, unpublished observations).
Administration of RMI 12,936 on Day 8 of pregnancy has been shown to produce significant ovarian hypertrophy in intact pregnant rats but not in pregnant hysterectomized or mature cyclic animals. Further investigation of this finding was necessary, however, as the experimental designs used allowed only within-experiment and not between-experiment comparisons (Kendle, 1975) . The present results extend the original observation to show that hysterectomy prevents the luteal develop¬ ment associated with normal pregnancy and also prevents the hypertrophy caused by RMI 12,936.
These findings are therefore compatible with the hypothesis that RMI 12,936 induces ovarian hyper¬ trophy in the pregnant animal through a luteotrophic factor of uterine origin, the production of which is confined to the pregnant uterus.
The investigations on induced corpora lutea in immature rats and mature pseudopregnant rats, however, indicated that significant ovarian hypertrophy followed administration of RMI 12,936 to these animals which had functional corpora lutea. It was considered to be unlikely that the capacity to produce a luteotrophic factor was shared by the mature pregnant uterus, the pseudopregnant uterus and the immature gonadotrophin-stimulated uterus but was absent from the uterus of the mature cyclic animal (Kendle, 1975 (Kendle, 1975) The present study provides further support for the original hypothesis (Kendle, 1975) that the antifertility effect of RMI 12,936 is due to antiprogestational activity and that the compound appears suitable for development as a contraceptive for dosage at monthly intervals. Further in¬ vestigation of the compound will therefore be undertaken. In particular, attempts will be made to elucidate the biochemical and histological effects on the ovary, the fate of the corpora lutea after Day 15 of pregnancy following administration on Day 8 and the nature of the uterine response to the compound.
